Immatics (NASDAQ:IMTXW) Sees Significant Decline in Short Interest

Immatics (NASDAQ:IMTXW) was the target of a significant decline in short interest during the month of March. As of March 31st, there was short interest totalling 58,900 shares, a decline of 21.9% from the March 15th total of 75,400 shares. Based on an average trading volume of 26,800 shares, the short-interest ratio is presently 2.2 days.

Immatics Price Performance

Shares of Immatics stock traded up $0.01 during trading on Friday, hitting $0.02. The stock had a trading volume of 700 shares, compared to its average volume of 24,568. Immatics has a 12 month low of $0.01 and a 12 month high of $4.00. The firm’s fifty day simple moving average is $0.03 and its 200-day simple moving average is $0.36.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.